Last reviewed · How we verify
NCT05287360
A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants
Phase 1 trial testing Rivoceranib in Healthy in 60 participants. Completed in 24 March 2022.
16 March 2022
Quick facts
| Lead sponsor | Elevar Therapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 60 |
| Start date | 30 December 2021 |
| Primary completion | 16 March 2022 |
| Estimated completion | 24 March 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Rivoceranib (Apatinib) — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Elevar Therapeutics — full company profile →
Who can join
Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this trial is to compare a single dose of 4 different rivoceranib tablets in healthy adult participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05287360
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rivoceranib
Trials testing the same drug.
- NCT07147101 — Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy · not yet recruiting
- NCT06308575 — A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma · Phase 2 · withdrawn
- NCT06200233 — Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor · Phase 2 · not yet recruiting
- NCT04985136 — A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patie · Phase 3 · terminated
- NCT04119453 — A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic C · Phase 2 · terminated
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Elevar Therapeutics trials
Trials by the same sponsor.
- NCT04526106 — REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced S · Phase 1, PHASE2 · completed
- NCT04119453 — A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic C · Phase 2 · terminated
- NCT04073615 — A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC) · Phase 1 · terminated
- NCT03707028 — A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gas · Phase 1, PHASE2 · terminated
- NCT03396211 — A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05287360 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Elevar Therapeutics
- Last refreshed: 18 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05287360.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing